|
To implement the annual National Supply Plan, the NBA has supply contracts with various suppliers of blood and blood related products which it manages closely to ensure that demand for product is always met.
Most plasma derived products used in Australia are manufactured by CSL Limited from plasma collected by the ARCBS under the Plasma Products Agreement. Australia is, however, totally reliant on an imported supply of plasma derived Factor XI and fXIII, anti-inhibitor coagulant complex concentrates, Protein C and a plasma-derived Rh(D) immunoglobulin product. These products are either not economical to manufacture in Australia or, as is the case for IVIg, the Australian system is unable to produce enough product to meet demand. IVIg is accordingly imported as a contingency to supplement domestic supply under a Standing Offer.
Related Documents
Privacy | Copyright | Disclaimer | Contact Us
This page last modified on January 6, 2009
National Blood Supply Contingency Plan (NBSCP)
Australia's Response to Blood Shortages
National Blood Sector Conference 08
Conference Proceedings
Australian Bleeding Disorders Registry (ABDR)
Procurement
- Provision of Internal Audit Services